MDXG gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. MDXG is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. MDXG scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make MDXG suitable for value investing!
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 9.97 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.25 | ||
| Fwd PE | 27.73 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.36 | ||
| EV/EBITDA | 13.15 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.93
+0.07 (+1.02%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.25 | ||
| Fwd PE | 27.73 | ||
| P/S | 2.61 | ||
| P/FCF | 15.36 | ||
| P/OCF | 15.13 | ||
| P/B | 4.3 | ||
| P/tB | 4.93 | ||
| EV/EBITDA | 13.15 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 9.97 |
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 19.25 and the Price/Book (PB) ratio is 4.3.
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.